Cantor Fitzgerald Estimates uniQure FY2025 Earnings

uniQure (NASDAQ:QURE) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for uniQure in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings per share of ($1.87) for the year. Cantor Fitzgerald has a “Overweight” rating and a $58.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million.

A number of other equities research analysts have also recently issued reports on the company. StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Mizuho boosted their target price on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. Finally, Leerink Partners raised their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

uniQure Stock Performance

Shares of QURE opened at $15.67 on Thursday. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock’s fifty day moving average price is $12.93 and its two-hundred day moving average price is $8.74. The firm has a market cap of $763.80 million, a PE ratio of -3.16 and a beta of 0.41.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its position in uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares in the last quarter. Sanders Morris Harris LLC raised its holdings in shares of uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 34,034 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in uniQure in the 4th quarter worth approximately $88,000. Franklin Resources Inc. purchased a new stake in uniQure in the third quarter worth approximately $7,360,000. Finally, Geode Capital Management LLC grew its position in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.